Want to see HK:6127 full AI Analyst Report?
6127 Stock Chart & Stats
HK$21.12
HK$0.01(0.12%)
At close: 4:00 PM EST
HK$21.12
HK$0.01(0.12%)
Day’s Range― - ―
52-Week RangeHK$15.13 - HK$29.98
Previous CloseN/A
Volume546.17K
Average Volume (3M)6.46M
Market Cap
HK$33.03B
Enterprise ValueHK$11.58K
Total Cash (Recent Filing)HK$2.49B
Total Debt (Recent Filing)HK$37.00M
Price to Earnings (P/E)62.6
Beta1.45
Next Earnings
Aug 29, 2026EPS Estimate
0.56Next Dividend Ex-DateN/A
Dividend Yield0.62%
Share Statistics
EPS (TTM)0.66
Shares Outstanding118,995,210
10 Day Avg. Volume2,397,586
30 Day Avg. Volume6,458,364
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.65
Price to Sales (P/S)8.31
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$23.00Price Target Upside8.90% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.73
Revenue Forecast (FY)HK$2.25B
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetThe near-zero debt position and large equity base give durable financial flexibility: supports capital spending on lab capacity, cushions cyclical revenue swings, lowers interest burden, and preserves optionality for M&A or R&D investments over the next 2–6 months.
Fee-for-service CRO Business ModelA fee-for-service CRO model tied to outsourced preclinical and regulatory work generates recurring, project-driven revenue from pharma/biotech clients. This structural demand from drug development pipelines underpins steadier long-run utilization of labs and staff versus transactional product businesses.
TTM Revenue Rebound With Positive ProfitabilityThe recent TTM rebound and sustained net profit margin indicate operational resilience and an ability to restore top-line momentum while remaining profitable, supporting margin recovery initiatives and reinforcing cash generation potential after prior contraction years.
Bears Say
Multi-year Top-line ContractionA multi-year revenue decline reduces predictability of future growth and suggests structural demand or market-share headwinds. Continued top-line weakness can limit scale economies, constrain reinvestment in capacity, and pressure long-term revenue visibility.
Sharp Gross Margin CompressionMaterial margin erosion implies weaker pricing power or rising input costs. Persistently lower gross margins would permanently reduce operating leverage and returns on capital, making it harder to fund growth or improve ROE absent structural cost or pricing fixes.
Volatile And Declining Free Cash FlowSignificant FCF volatility and the recent sharp decline weaken confidence in cash available for capex, working-capital needs, or shareholder returns. Unstable cash conversion raises refinancing or funding risk if growth or working-capital needs rise.
JOINN Laboratories (China) Co., Ltd. Class H News
6127 FAQ
What was JOINN Laboratories (China) Co., Ltd. Class H’s price range in the past 12 months?
JOINN Laboratories (China) Co., Ltd. Class H lowest stock price was HK$15.13 and its highest was HK$29.98 in the past 12 months.
What is JOINN Laboratories (China) Co., Ltd. Class H’s market cap?
JOINN Laboratories (China) Co., Ltd. Class H’s market cap is HK$33.03B.
When is JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date?
JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date is Aug 29, 2026 which is in 20 days.
How were JOINN Laboratories (China) Co., Ltd. Class H’s earnings last quarter?
JOINN Laboratories (China) Co., Ltd. Class H released its earnings results on Apr 29, 2026. The company reported HK$0.367 earnings per share for the quarter, beating the consensus estimate of HK$0.069 by HK$0.298.
Is JOINN Laboratories (China) Co., Ltd. Class H overvalued?
According to Wall Street analysts JOINN Laboratories (China) Co., Ltd. Class H’s price is currently Undervalued.
Does JOINN Laboratories (China) Co., Ltd. Class H pay dividends?
JOINN Laboratories (China) Co., Ltd. Class H pays a Annually dividend of HK$0.138 which represents an annual dividend yield of 0.62%. See more information on JOINN Laboratories (China) Co., Ltd. Class H dividends here
What is JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate?
JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate is 0.56.
How many shares outstanding does JOINN Laboratories (China) Co., Ltd. Class H have?
JOINN Laboratories (China) Co., Ltd. Class H has 118,995,210 shares outstanding.
What happened to JOINN Laboratories (China) Co., Ltd. Class H’s price movement after its last earnings report?
JOINN Laboratories (China) Co., Ltd. Class H reported an EPS of HK$0.367 in its last earnings report, beating expectations of HK$0.069. Following the earnings report the stock price went down -1.439%.
Which hedge fund is a major shareholder of JOINN Laboratories (China) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6127
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JOINN Laboratories (China) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.02%
12-Months-Change
Fundamentals
Return on Equity
0.62%
Trailing 12-Months
Asset Growth
12.65%
Trailing 12-Months
Company Description
JOINN Laboratories (China) Co., Ltd. Class H
Joinn Laboratories (China) Co., Ltd. is a global provider of essential preclinical and non-clinical research services, operating across the United States, mainland China, and various international markets. The company organizes its operations into three primary divisions: Non-Clinical Studies, Clinical Trial and Related Services, and Research Model Sales. The Non-Clinical Studies segment specializes in comprehensive drug safety assessments, pharmacokinetic and drug metabolism research, and pharmacology and efficacy investigations. Within its Clinical Trial and Related Services segment, the firm delivers clinical contract research organization (CRO) support, co-manages specialized Phase I clinical research facilities, and provides bioanalytical testing. The Research Model Sales division is responsible for the development, breeding, and distribution of diverse animal models for research purposes, encompassing non-human primates and rodents. Furthermore, Joinn Laboratories also extends its offerings to include investment management and cell-based assay (CBA) services. Established in 1995, the company is headquartered in Beijing, China.
6127 Stock 12 Month Forecast
Average Price Target
HK$23.00
▲(8.90% Upside)
Technical Analysis
Genscript Biotech
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―